Shield Therapeutics PLC: FDA approves broad label for Feraccru
Shield Therapeutics (LON:STX) reports it has achieved the best possible outcome for Feraccru. The US Food & Drug Administration (FDA) has approved the treatment for a broad label to treat iron deficiency (ID) in adults, addressing a population many times wider than the iron deficiency anaemia (IDA) indications included in the submission data.
Feraccru, an oral treatment for iron deficiency with or without anaemia that will be marketed as Accrufer in the US, is now positioned to directly challenge the market-leading intravenous iron therapy. This is backed by clinical non-inferiority, as well as being a potentially safer and more convenient alternative. STX is well supported to negotiate attractive deal terms with prospective US commercial partners for Accrufer in a total US prescription iron replacement market worth more than US$1bn.
Feraccru, which will be marketed as Accrufer in the US, has obtained the broadest possible label for treating adults with iron deficiency with or without anaemia. There are around three times as many patients with ID than with IDA (source: STX). Adding these, the total addressable population could reach up to 40 million in the US. The announced label also took off the table the prospective limitation to just chronic kidney disease (CKD) and inflammatory bowel disease (IBD) patients as per the studies included in the FDA approval submission. In all Accrufer is poised to approach a US iron replacement therapy prescription market worth more than US$1bn.
The key commercial and clinical considerations supporting Accrufer are its greater convenience compared to intravenous (IV) iron therapy, for those patients unable to tolerate first-line salt-based oral iron treatments. Data from the AEGIS head-to-head (H2H) multi-national Phase IIIb randomised, active-controlled trial, showed non-inferiority to Vifor Pharma’s market-leading IV iron Ferinject (marketed in the US as Injectafer). IV iron is invasive and inconvenient since it needs to be administered in a hospital because it always carries the risk of a severe and potentially fatal allergic reaction.
Furthermore, in the US, Injectafer has a more specific label than Accrufer – the former is indicated first for adults with IDA, for patients who have non-dialysis dependent CKD, and for patients who are intolerant to, or who have an unsatisfactory response to oral irons. Accrufer’s broader label, therefore, favours its commercial prospects.
Quick facts: Shield Therapeutics PLC
Price: 153 GBX
Market Cap: £179.3 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE